AI-generated summary
In a mouse model of sepsis-induced acute lung injury, the authors report that 650 nm red-light therapy prolonged survival, reduced lung edema and inflammatory markers, and was associated with changes in immune cell profiles and higher adiponectin levels. Cell experiments suggested improved mitochondrial function, and effects were reduced when AdipoR1 was knocked down. The study was conducted in mice and cultured macrophages, so the findings may not apply to humans.
- Who or what was studied
- Mice with cecal ligation and puncture-induced sepsis and RAW264.7 macrophage cultures
- Wavelengths
- 650 nm
- Limits stated in the abstract
- The study used animal and cultured cell models only, so its findings cannot be directly extended to human patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Sepsis-induced acute lung injury (ALI) is driven by dysregulated innate immunity and mitochondrial dysfunction. Monocyte/macrophage trafficking and polarization critically shape disease trajectory, yet clinically tractable immunometabolic interventions are limited. We hypothesized that 650 nm red-light photobiomodulation (PBM) alleviates septic ALI by reprogramming myeloid responses and preserving mitochondrial function via adiponectin signaling.
Methods
Septic ALI was induced by cecal ligation and puncture (CLP) in mice. Animals received 650 nm PBM (10 min, every 6 h, three times within 24 h). Survival, lung edema, histology, and serum cytokines were assessed. Lung chemokines/cytokines were profiled by 23-plex Luminex. Immune composition was analyzed by flow cytometry, and CCR2+/CX3CR1+ subsets were visualized in CcrRFP-Cx3cr1GFP mice using 3D cryo-fMOST. IHC quantified CX3CR1, CCR2, CD68, CD86, and CD206. Adiponectin was measured in serum/BALF and lung. Pathway relevance was tested by AdipoR1 siRNA. In LPS-stimulated RAW264.7 macrophages, PBM effects on cytokines, ATP, mitochondrial ROS (MitoSOX), membrane potential (JC-1), and MitoTracker fluorescence were evaluated, with/without AdipoR1 knockdown.
Results
PBM prolonged survival, reduced lung edema, improved histopathology, and lowered systemic TNF-α, IL-6, IL-1β, and MCP-1. Luminex showed broad suppression of pro-inflammatory mediators (e.g., G-/GM-CSF, IL-1 family, IL-6, IL-12, IL-17A, TNF-α) and chemokines (CCL11, CXCL1, MCP-1/CCL2, CCL3/4/5), with increases in IL-4/IL-10/IL-13. Flow cytometry revealed decreased neutrophils, monocytes, and inflammatory macrophages, alongside restored eosinophils and resident macrophages. Cryo-fMOST and IHC demonstrated reduced CCR2+/CD86+ inflammatory cells and enrichment of CX3CR1+/CD206+ reparative cells. PBM elevated adiponectin in serum, BALF, and lung; AdipoR1 knockdown abrogated anti-inflammatory effects and myeloid rebalancing. In vitro, PBM dose-dependently suppressed LPS-induced TNF-α/IL-6 and IL-1β while increasing IL-10, restored ATP, reduced mitochondrial ROS, and improved membrane potential, that benefits lost with AdipoR1 silencing.
Conclusions
Septic ALI modulated by 650 nm PBM was characterized by suppressing CCR2+ inflammatory recruitment, enriching CX3CR1+/M2-like macrophages, and preserving mitochondrial function through adiponectin-AdipoR1 signaling. These data position red-light PBM as a mechanistically grounded, non-invasive method for sepsis-associated lung injury.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 650 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Reactive oxygen species, Adenosine triphosphate, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.